Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers
As a multidimensional metabolic disorder, the disability and death rate of type 2 diabetes mellitus (T2DM) has increased over time. T2DM covers a wide range of pathological manifestations ranging from hyperglycemia to multi-organ failure, and it has the potential to evolve into acute complications,...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1501305/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850189429974499328 |
|---|---|
| author | Chuanxin Liu Hetao Chen Hetao Chen Yujin Ma Lei Zhang Lulu Chen Lulu Chen Jiarui Huang Zizhe Zhao Hongwei Jiang Jiao Kong |
| author_facet | Chuanxin Liu Hetao Chen Hetao Chen Yujin Ma Lei Zhang Lulu Chen Lulu Chen Jiarui Huang Zizhe Zhao Hongwei Jiang Jiao Kong |
| author_sort | Chuanxin Liu |
| collection | DOAJ |
| description | As a multidimensional metabolic disorder, the disability and death rate of type 2 diabetes mellitus (T2DM) has increased over time. T2DM covers a wide range of pathological manifestations ranging from hyperglycemia to multi-organ failure, and it has the potential to evolve into acute complications, including ketosis and chronic complications such as peripheral neuropathy, retinopathy, and nephropathy. T2DM mainly occurs in microvascular and large vessels and thus it is restricted for the clinician to diagnose and prescribe. However, the pathological mechanism and clinical diagnosis are inadequate. High-throughput metabolomics, characterized by non-invasive diagnostic techniques to identify potential biomarkers and distinct stages of T2DM, has been increasingly recognized as a vigorous tool with latent capacity for clinical translation. The pathological stratification of T2DM can significantly reduce disability and mortality rates. By tracing the metabolome and associated pathways from impaired fasting blood glucose or impaired glucose tolerance to severe organ failure, the chief contributions of large, independent population-based cohorts are summarized herein. These results facilitate understanding the pathophysiology and mechanism and supports research in accurate diagnosis, risk prediction, curative effect, distinct stages, and prognosis judgment of T2DM. |
| format | Article |
| id | doaj-art-dc3b744fc73148dfa35b97e35c870119 |
| institution | OA Journals |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-dc3b744fc73148dfa35b97e35c8701192025-08-20T02:15:37ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-02-011610.3389/fendo.2025.15013051501305Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkersChuanxin Liu0Hetao Chen1Hetao Chen2Yujin Ma3Lei Zhang4Lulu Chen5Lulu Chen6Jiarui Huang7Zizhe Zhao8Hongwei Jiang9Jiao Kong10Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, ChinaLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, ChinaDepartment of Clinical Laboratory, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, ChinaLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, ChinaDepartment of Integrative Medicine, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, ChinaLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, ChinaDepartment of Clinical Laboratory, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, ChinaDepartment of Critical Care Medicine, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, ChinaLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, ChinaLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, ChinaInstitute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaAs a multidimensional metabolic disorder, the disability and death rate of type 2 diabetes mellitus (T2DM) has increased over time. T2DM covers a wide range of pathological manifestations ranging from hyperglycemia to multi-organ failure, and it has the potential to evolve into acute complications, including ketosis and chronic complications such as peripheral neuropathy, retinopathy, and nephropathy. T2DM mainly occurs in microvascular and large vessels and thus it is restricted for the clinician to diagnose and prescribe. However, the pathological mechanism and clinical diagnosis are inadequate. High-throughput metabolomics, characterized by non-invasive diagnostic techniques to identify potential biomarkers and distinct stages of T2DM, has been increasingly recognized as a vigorous tool with latent capacity for clinical translation. The pathological stratification of T2DM can significantly reduce disability and mortality rates. By tracing the metabolome and associated pathways from impaired fasting blood glucose or impaired glucose tolerance to severe organ failure, the chief contributions of large, independent population-based cohorts are summarized herein. These results facilitate understanding the pathophysiology and mechanism and supports research in accurate diagnosis, risk prediction, curative effect, distinct stages, and prognosis judgment of T2DM.https://www.frontiersin.org/articles/10.3389/fendo.2025.1501305/fullclinical metabolomicstype 2 diabetes mellitus (T2DM)complicationsbiomarkersstratification |
| spellingShingle | Chuanxin Liu Hetao Chen Hetao Chen Yujin Ma Lei Zhang Lulu Chen Lulu Chen Jiarui Huang Zizhe Zhao Hongwei Jiang Jiao Kong Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers Frontiers in Endocrinology clinical metabolomics type 2 diabetes mellitus (T2DM) complications biomarkers stratification |
| title | Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers |
| title_full | Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers |
| title_fullStr | Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers |
| title_full_unstemmed | Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers |
| title_short | Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers |
| title_sort | clinical metabolomics in type 2 diabetes mellitus from pathogenesis to biomarkers |
| topic | clinical metabolomics type 2 diabetes mellitus (T2DM) complications biomarkers stratification |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2025.1501305/full |
| work_keys_str_mv | AT chuanxinliu clinicalmetabolomicsintype2diabetesmellitusfrompathogenesistobiomarkers AT hetaochen clinicalmetabolomicsintype2diabetesmellitusfrompathogenesistobiomarkers AT hetaochen clinicalmetabolomicsintype2diabetesmellitusfrompathogenesistobiomarkers AT yujinma clinicalmetabolomicsintype2diabetesmellitusfrompathogenesistobiomarkers AT leizhang clinicalmetabolomicsintype2diabetesmellitusfrompathogenesistobiomarkers AT luluchen clinicalmetabolomicsintype2diabetesmellitusfrompathogenesistobiomarkers AT luluchen clinicalmetabolomicsintype2diabetesmellitusfrompathogenesistobiomarkers AT jiaruihuang clinicalmetabolomicsintype2diabetesmellitusfrompathogenesistobiomarkers AT zizhezhao clinicalmetabolomicsintype2diabetesmellitusfrompathogenesistobiomarkers AT hongweijiang clinicalmetabolomicsintype2diabetesmellitusfrompathogenesistobiomarkers AT jiaokong clinicalmetabolomicsintype2diabetesmellitusfrompathogenesistobiomarkers |